Immunisations
Statistical Publication Notice
Thursday 25 March 2010.
Childhood immunisation uptake rates, quarter and year ending 31 December 2009
INTRODUCTION
KEY POINTS
- In Scotland as a whole, quarterly uptake rates by 24 months of age for primary courses of diphtheria, tetanus, pertussis, polio, Hib, MenC and PCV remain high and stable at around 96% to 98%.
- Quarterly uptake of one dose of MMR by 24 months is 94.2%. This is an increase of 0.4 percentage points on the previous quarterly figure. Quarterly uptake by 5 years of age is 96.6%, an increase of 0.4 percentage points on the previous quarter.
- Quarterly uptake of the Hib/MenC booster by 24 months is 94.2%, a slight decrease of 0.1 percentage points on the previous quarterly figure. Quarterly uptake of the PCV booster by 24 months is 94.9%, a slight increase of 0.1 percentage points on the previous quarterly figure.
INTERPRETATION
In Scotland uptake rates for the childhood booster vaccines (diphtheria, tetanus, pertussis and polio, and the second dose of MMR (MMR2)), have historically been reported by 6 years of age. In line with figures for the rest of the UK, from quarter ending December 2006, uptake rates for these vaccines are now reported by 5 years of age. For trend purposes, reporting by 6 years of age will also continue to be presented.
For details of Scotland's routine childhood immunisation timetable see Immunisation Schedule.
DETAILED FINDINGS
For the quarter ending 31 December 2009, at Scotland level:
Uptake rates by 12 months of age (born 1 October to 31 December 2008)
- Uptake rates by 12 months of age for primary courses of diphtheria, tetanus, pertussis, polio, Hib, MenC and PCV remain above 95%.
Uptake rates by 24 months of age (born 1 October to 31 December 2007)
- Uptake rates by 24 months of age for primary courses of diphtheria, tetanus, pertussis, polio, Hib, MenC and PCV remain high and stable at around 96% to 98%.
- The combined Hib/MenC booster (normally given at around 12 months of age) was introduced in September 2006. This required the inclusion of an additional immunisation appointment in the childhood schedule. Uptake of this vaccine by 24 months remains stable at around 94%.
- A booster dose of PCV was also introduced in September 2006 (normally given at the same appointment as the first dose of MMR at around 13 months of age). Uptake for this vaccine by 24 months of age is 94.9%, an slight increase of 0.1 percentage points on the previous quarterly figure.
- Uptake of one dose of MMR (MMR1) by 24 months is 94.2% (up by 0.4 percentage points on the previous quarterly figure of 93.8%). MMR1 uptake rates by 24 months have continued to be above 90% since autumn 2005.
Uptake rates by 5 years of age (born 1 October to 31 December 2004)
- Uptake of one dose of MMR (MMR1) by 5 years is 96.6% (up by 0.4 percentage points on the previous quarterly figure of 96.2%). This once again exceeds the 95% target. By 24 months the reported uptake for this cohort of children was 92.8% showing that a significant number of children are immunised beyond the standard age.
- Uptake of the second dose of MMR (MMR2) by 5 years old is 91.6%. This is an increase of 1.5 percentage points on the previous quarter when the rate was 90.1%. Other pre-school booster vaccines experienced a similar rise (from 92.6% to 93.6%).
This release also provides an update to annual immunisation uptake rates to show data for the year ending 31 December 2009, and includes rates by deprivation.
- Deprivation has some effect on uptake rates: annual uptake of the primary immunisations by 12 months of age among children in the most deprived areas is around 1 percentage point lower than uptake in the least deprived areas. However, even in the most deprived areas, uptake rates for all primary immunisations by 12 months are high, at around 96%.
MAIN CONTACTS:
Ruth Gordon
Senior Information Analyst
Child Health Information Team
0131 275 6335
r.gordon@nhs.net
Judith Tait
Child Health Information Team Leader
0131 275 6833
judith.tait@nhs.net
GLOSSARY:
MMR - Measles, Mumps, Rubella
Pertussis - Whooping cough
Hib - Haemophilus influenzae type b
MenC - Meningitis C
PCV - Pneumococcal Conjugate Vaccine
PRE-RELEASE ACCESS:
NHS Board Chief Executives
NHS Board Communication leads
Health Protection Scotland
ScotPHN Co-ordinator, Health Scotland
NHS Board Immunisation Co-ordinators
Medical Director, Health Protection Scotland
Epidemiologist (Immunisation), Health Protection Scotland
This extended Pre-Release Access is given to a small number of named individuals in the Scottish Government Health Department (Analytical Services Division). This Pre-Release Access is for the sole purpose of enabling that department to gain an understanding of the statistics prior to briefing others in Scottish Government (during the period of standard Pre-Release Access).
HISTORY OF THIS PUBLICATION:
Last Published: 15 December 2009
Next Due: June 2010
Data Available Since: March 1995
Ruth Gordon
Printer friendly version